English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

As of April 15, 2020 there were 1,914,916 confirmed cases of coronavirus disease 2019 (COVID-19) responsible for 123,010 deaths throughout the world. Facing mortality rates near 5%, the global medical community is racing to develop effective therapies against this viral pandemic. Current management of COVID-19 is largely supportive, with interventions directed at prevention and treatment of severe pulmonary complications including Acute Respiratory Distress Syndrome (ARDS), the leading cause of mortality in the disease. A small epidemiologic study of an early cohort of patients with laboratory-confirmed disease suggested a correlation between cytokine-driven inflammation and disease severity with progression to ARDS.3 Here we present the case of an acutely ill patient diagnosed with COVID-19 pneumonia who was successfully treated with a supportive care regimen which included tocilizumab.

Successful Treatment of COVID-19 Pneumonia using Hydroxychloroquine, Azithromycin, and Tocilizumab